TY - JOUR T1 - The Prognostic Value of Systemic Inflammatory Markers in Advanced Renal Cell Carcinoma Patients Treated With Molecular Targeted Therapies JF - Anticancer Research JO - Anticancer Res SP - 1739 LP - 1745 DO - 10.21873/anticanres.14127 VL - 40 IS - 3 AU - KOSUKE UEDA AU - NAOYUKI OGASAWARA AU - SATORU YONEKURA AU - YOSHIHIRO MATSUNAGA AU - RYUJI HOSHINO AU - HIROFUMI KUROSE AU - KATSUAKI CHIKUI AU - KEIICHIRO UEMURA AU - MAKOTO NAKIRI AU - KIYOAKI NISHIHARA AU - MITSUNORI MATSUO AU - SHIGETAKA SUEKANE AU - TSUKASA IGAWA Y1 - 2020/03/01 UR - http://ar.iiarjournals.org/content/40/3/1739.abstract N2 - Background/Aim: The present study examined the impact of systemic inflammatory markers including C-reactive protein (CRP)/Albumin (Alb) and neutrophil lymphocyte ratio (NLR)/Alb on the prognosis of patients treated with first line molecular targeted therapy for advanced RCC. Patients and Methods: A total of 131 patients with advanced RCC treated with molecular targeted therapy as first line treatment from May 2008 to April 2019 were retrospectively analyzed. Results: High CRP, high NLR, low Alb and high CRP/Alb showed significantly worse progression-free survival (PFS) and overall survival (OS) than low CRP, low NLR, high Alb, low CRP/Alb and low NLR/Alb, respectively. In multivariate analyses, prior nephrectomy (p=0.0321) and NLR/Alb ratio (p=0.0327) were independent prognostic factors for PFS. Furthermore, prior nephrectomy (p=0.0013) and CRP/Alb ratio (p=0.0020) were independent prognostic factors for OS. Conclusion: CRP/Alb and NLR/Alb ratios are useful and independent prognostic biomarkers in patients with advanced RCC treated with molecular targeted therapy. ER -